Histological score for cells with irregular nuclear contours for the diagnosis of reflux esophagitis in children

Pharmacogenomics fail to explain proton pump inhibitor refractory esophagitis in pediatric esophageal atresia

BACKGROUND

Esophagitis is prevalent in patients with esophageal dysmotility despite acid suppression, likely related to poor esophageal clearance. Esophageal atresia (EA) is a classic model of dysmotility where this observation holds true. In adult non-dysmotility populations, failure of esophagitis to respond to proton pump inhibitors (PPI) has been linked to variants in CYP2C19 that influence the activity of the encoded enzyme. It is unknown if CYP2C19 metabolizer phenotype contributes to PPI-refractory, non-allergic esophagitis in EA.

METHODS

We performed a cross-sectional study of 314 children with (N = 188) and without (N = 126) EA who were on PPI therapy at the time of endoscopy to evaluate for possible gastroesophageal reflux disease. Patients with eosinophilic esophagitis and/or fundoplication were excluded. Clinical and histology data were collected. Genomic DNA from biopsy samples was genotyped for polymorphisms in CYP2C19.

RESULTS

CYP2C19 metabolizer phenotypes were not associated with presence or severity of esophagitis (P = 0.994). In a multivariate logistic regression adjusted for potential confounders, EA was the strongest and only significant predictor of esophagitis (odds ratio 2.72, P = 0.023). Using negative binomial regression, we found that CYP2C19 phenotype was not a significant predictor of eosinophil count in children with PPI-refractory esophagitis.

CONCLUSIONS

Patients with EA are significantly more likely to experience PPI-refractory, non-allergic esophagitis than controls regardless of CYP2C19 metabolizer phenotype, suggesting that factors other than CYP2C19 genetics, including dysmotility, are the primary drivers of esophagitis in EA. CYP2C19 genotype failed to predict PPI-refractory, non-allergic esophagitis in both EA and non-EA children.

Esophagitis in Pediatric Esophageal Atresia: Acid May Not Always Be the Issue

OBJECTIVE

Esophagitis is highly prevalent in patients with esophageal atresia (EA). Peptic esophagitis has long been assumed to be the primary cause of esophagitis in this population, and prolonged acid suppressive medication usage is common; such treatment is of unknown benefit and carries potential risk.

METHODS

To better understand the role of commonly used antireflux treatments in EA, we analyzed all patients with repaired EA who underwent endoscopy with biopsies at our institution between January 2016 and August 2018. Macroscopic erosive and histologic esophagitis on biopsy was graded per predefined criteria. Clinical characteristics including acid suppressive medication usage, type of EA and repair, presence of hiatal hernia, and history of fundoplication were reviewed.

RESULTS

There were 310 unique patients (33.5% long gap EA) who underwent 576 endoscopies with biopsies during the study period. Median age at endoscopy was 3.7 years (interquartile range 21-78 months). Erosive esophagitis was found in 8.7% of patients (6.1% of endoscopies); any degree of histologic eosinophilia (≥1 eosinophil/high power field [HPF]) was seen in 56.8% of patients (48.8% of endoscopies), with >15 eosinophils/HPF seen in 15.2% of patients (12.3% of endoscopies). Acid suppression was common; 86.9% of endoscopies were preceded by acid suppressive medication use. Fundoplication had been performed in 78 patients (25.2%). Proton pump inhibitor (PPI) and/or H2 receptor antagonist (H2RA) use were the only significant predictors of reduced odds for abnormal esophageal biopsy (P = 0.011 for PPI, P = 0.048 for H2RA, and P = 0.001 for PPI combined with H2RA therapy). However, change in intensity of acid suppressive therapy by either dosage or frequency was not significantly associated with change in macroscopic erosive or histologic esophagitis (P > 0.437 and P > 0.13, respectively). Presence or integrity of a fundoplication was not significantly associated with esophagitis (P = 0.236).

CONCLUSIONS

In EA patients, acid suppressive medication therapy is associated with reduced odds of abnormal esophageal biopsy, though histologic esophagitis is highly prevalent even with high rates of acid suppressive medication use. Esophagitis is likely multifactorial in EA patients, with peptic esophagitis as only one of multiple possible etiologies for esophageal inflammation. The clinical significance of histologic eosinophilia in this population warrants further investigation.

Adult and paediatric GERD: diagnosis, phenotypes and avoidance of excess treatments

Detailed investigations and objective measurements in patients with symptoms of gastro-oesophageal reflux should be performed with the intent of making the correct diagnosis, thus enabling choice of appropriate therapy. Establishing the most effective therapy is particularly important in adults who do not respond to standard treatment and in children. The use of PPIs for suspected GERD has increased substantially over the past decade, providing great relief in patients with acid-related symptoms, but also leading to adverse effects and a considerable economic burden. Adults with functional heartburn do not benefit from PPIs, while prolonged PPI use in patients with extraoesophageal symptoms remains a controversial area. Moreover, PPIs are not indicated in infants with GERD unless symptoms are proven to be acid-related. With regard to antireflux surgery, patients must be carefully selected to avoid the need for ongoing PPI treatment postoperatively. Correct diagnosis and phenotyping of patients with symptoms attributed to gastro-oesophageal reflux through detailed investigations is therefore imperative, leading to improved patient outcomes and rationalized use of available treatment options. In this Review, we outline currently available diagnostic tests and discuss approaches to limit any unnecessary medical or surgical interventions.

Proposal of a histopathological predictive rule for the differential diagnosis between American tegumentary leishmaniasis and sporotrichosis skin lesions

BACKGROUND

American tegumentary leishmaniasis (ATL) and sporotrichosis exhibit similar histopathology and low frequencies of microorganism detection.

OBJECTIVES

This study seeks to identify microscopic alterations that can distinguish between these diseases.

METHODS

Haematoxylin and eosin stained slides of 171 ATL and 97 sporotrichosis samples from active cutaneous lesions were examined for histopathological alterations. The lesions were diagnosed by isolating the agent (which was not visible) in culture. An intuitive diagnosis was assigned to each slide. The strength of the association between the histopathological findings and the diagnosis was estimated by an odds ratio, and each finding was graded according to a regression model. A score was assigned to each sample based on the histopathological findings. A study of the interobserver reliability was performed by calculating kappa coefficients of the histopathological findings and intuitive diagnoses.

RESULTS

The markers 'macrophage concentration', 'tuberculoid granuloma' and 'extracellular matrix degeneration' were associated with ATL. 'Suppurative granuloma', 'stellate granuloma', 'different types of giant cells', 'granulomas in granulation tissue' and 'abscess outside the granuloma' were associated with a diagnosis of sporotrichosis. 'Macrophage concentration' and 'suppurative granuloma' had the highest (substantial and almost perfect, respectively) reliability. The regression model score indicated 92.0% accuracy. The intuitive diagnosis had 82.5% diagnostic accuracy and substantial reliability.

CONCLUSIONS

Taking into account the clinical and epidemiological context, some histopathological alterations might be useful for the differential diagnosis between ATL and sporotrichosis cutaneous lesions in cases in which the aetiological agent is not visible.

The yield of a continuously patent gastroesophageal junction during upper endoscopy as a predictor of esophagitis in children

BACKGROUND AND AIMS

Over the last years we have noted an association between the endoscopic finding of a continuously patent gastroesophageal junction (GEJ) throughout the procedure and macroscopic or microscopic esophagitis. We could not find documentation for these endoscopic findings as a predictor of esophagitis in the literature. We aimed to find an association between these findings and microscopic and macroscopic esophagitis.

METHODS

During upper endoscopy, we routinely observe the GEJ for about 60 s and note the behavior of the GEJ and esophageal contractions. Patients with a persistently patent GEJ were recorded. A group of patients referred for upper endoscopy for reasons other than suspected reflux, whose esophagus was normal, and patients with reflux symptoms served as a control groups.

RESULTS

We found 21 patients (3.0%) in whom a patent GEJ had been noted. No significant age differences were noted between study and control groups. Eighteen out of 21 patients (86%) in the study group had varying degrees of microscopic esophagitis ranging from mild to severe (ten with mild esophagitis, three with moderate esophagitis, and five with severe esophagitis). Interestingly, ten out of 18 (55%) study patients with esophagitis on biopsies had no evidence of additional esophageal abnormality. Although all control patients had a normally appearing esophagus on upper endoscopy, 8/26 (31%) had mild esophagitis on biopsies. Differences were statistically significant (p < 0.001).

CONCLUSIONS

A continuously patent GEJ predicts quite accurately the presence of esophagitis in biopsies and may serve an additional endoscopic finding for the diagnosis of esophagitis especially non-erosive GER.

Redefining the role of lymphocytes in gastroesophageal reflux disease and eosinophilic esophagitis

Eosinophilic esophagitis (EoE) and reflux esophagitis (RE) overlap clinically and histologically. RE is characterized by epithelial infiltration with small numbers of neutrophils and eosinophils, EoE by a prominent eosinophilic infiltrate. Lymphocytic esophagitis (LE), a new entity characterized by peripapillary lymphocytosis, questions the role lymphocytes play in esophageal inflammation. We test the hypothesis that lymphocyte infiltration in RE differs from EoE. One blinded pathologist read esophageal biopsies from 39 RE and 39 EoE patients. Both groups demonstrated significant numbers of lymphocytes (RE 22.7 +/- 2.2/HPF, EoE 19.8 +/- 1.8/HPF). Eosinophils/HPF in RE and EoE were 2.8 +/- 0.7 and 74.9 +/- 8.2, respectively (P < 0.001). Neutrophils were uncommon in RE (0.26 +/- 0.16/HPF) and EoE (0.09 +/- 0.04; P = 0.07). Eight of the 39 RE specimens had >or=50 lymphocytes in >or=1 HPF. Two were consistent with LE. There was an inverse correlation between numbers of eosinophils and lymphocytes in EoE (R = -0.47; P = 0.002), and no correlation between them in RE (R = 0.18; P = 0.36). The patients with EoE who used antireflux medications had fewer lymphocytes (16.3 +/- 1.3 vs 22.2 +/- 2.3/HPF; P = 0.030) and eosinophils (55.6 +/- 5.2 vs 76.0 +/- 8.7/HPF; P = 0.042) than those who did not. The pathological role of lymphocytes in RE and EoE may be underestimated. Our observation that 5% of the RE specimens meet histopathological criteria for LE potentially blurs the line between these entities. The observation that eosinophil counts are lower in EoE when antireflux meds are used supports the notion that reflux plays a role in the clinical expression of EoE.

Expression of motilin and vasoactive intestinal peptide in gastric mucosa of patients with primary bile reflux gastritis

AIM: To investigate the expression of motilin and vasoactive intestinal peptide (VIP) in gastric mucosa of patients with primary bile reflux gastritis.

METHODS: Seventy-four patients with primary bile reflux gastric were divided into low reflux group (n = 42) and high reflux group (n = 32). A control group was composed of 28 subjects who showed no abnormalities during 24-hour gastric bilirubin monitoring with Bilitec 2000 and gastroscopic examination. The expression of motilin and VIP in biopsy specimens was detected by immunohistochemistry and analyzed using pathology image analysis software.

RESULTS: The expression levels of motilin in the high and low reflux groups were lower than that in the control group (558.93 ± 223.63 and 787.09 ± 252.97 vs 941.50 ± 275.87, respectively; both P < 0.05), while the expression levels of VIP in the high and low reflux groups were higher than in the control group (1700.06 ± 486.55 and 1241.19 ± 359.34 vs 959.00 ± 335.78, respectively; both P < 0.01). The detection rates of metaplasia atrophy in the high and low reflux groups were higher than that in the control group (50.0% and 26.2% vs 7.1%, respectively; P < 0.01 and 0.05). Patients with metaplastic atrophic gastritis had higher reflux rate than those with superficial gastritis (59.3% vs 30.5%, P < 0.05). The detection rate of Helicobacter pylori (H. pylori) decreased with the aggravation of bile reflux (64.3% and 47.6% vs 25.0%, respectively; P < 0.01 and 0.05).

CONCLUSION: The parasecretion of motilin and VIP may play a role in the development of bile reflux gastritis. Bile reflux is one of the risk factors for gastric mucosa injury. Bile reflux can inhibit the infection of H. pylori.

Relationship of Helicobacter pylori related gastritis, gut hormones and gastroesophageal reflux disease

AIM: To evaluate the relationship of H. pylori infection, H. pylori -related gastritis, serum gastrin and motilin levels and esophageal lesions in gastroesophageal reflux disease (GERD).

METHODS: All 53 GERD patients were divided into non-erosive reflux disease (NERD group, 32 cases) and reflux esophagitis (RE group, 21 cases ) by endoscopy. The degrees of gastritis in antrum and body as well as esophagitis were evaluated by pathological examinations. Fasting serum gastrin and motilin concentrations were determined by radioimmunoassay. H. pyloriwas examined by serum H. pylori-antibody, Warthin-Starry stain, urease-dependent test (rapid urease test or ¹⁴C-breath test).H. pylori infection was affirmed when at least two of three tests were positive. 20 normal persons were as controls. In NERD group, 18 were H. pylori positive and 14 were negative. In RE group 12 were H. pylori positive and 9 were negative. According to the classification of esophagitis, 11 were ClassⅠ, 7 ClassⅡ and 3 Class Ⅲ. There were 30 H. pylori (+) and 23 H. pylori (-) in 53 GERD patients.

RESULTS: As compared with healthy controls, fasting serum motilin levels in RE group were significantly lower (360±126 vs 440±110 mg/L, ^aP < 0.05) and those in NERD group were similar (P > 0.05). No differences in gastrin levels were found between NERD or RE group and controls (both P > 0.05). The serum gastrin levels in H. pylori (+) GERD were significantly higher than controls (35.8±11.6 vs 28.5±10.6 mg/L, ^bP < 0.05). In H. pylori (+) GERD patients, gastritis grades in the antrum and gastric body were significantly higher than that in H. pylori (-) patients (χ² = 32.97, χ² = 15.67, both P < 0.005). The esophagitis grades were similar in H. pylori (+) and H. pylori (-) GERD (χ² = 0.82, P > 0.05). The gastritis grades were not associated with the esophagitis degrees, but with H. pylori infection.

CONCLUSION: Motilin is involved in the pathogenesis of RE. H. pylori can lead to hypergastrinemia and gastritis in the antrum and gastric body.